We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

5344:TSEMARUWA CO., LTD. Analysis

Data as of 2026-03-15 - not real-time

NT$14.00

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

The stock is trading at TWD 14, which sits just above the 20‑day SMA (≈14.20) and the 200‑day SMA (≈14.19) but slightly below the 50‑day SMA (≈14.59), suggesting a neutral price stance. RSI sits at 45.7, indicating neither overbought nor oversold conditions, while the MACD line has just crossed above its signal line, producing a tiny positive histogram and a bullish signal. Volume is on an upward trend, yet the 30‑day volatility is high at roughly 33%, and the beta of around 0.5‑0.7 points to modest market sensitivity. Support is anchored near 13 and resistance near 15.1, framing a narrow trading range as market sentiment leans toward Greed (fear‑greed index 72.9).
Fundamentally, the company posted 12% revenue growth but suffers from thin gross margins (≈5.7%) and negative operating and profit margins, with a trailing EPS of –0.39 and an EBITDA of only TWD 16.4 M. The balance sheet shows ample cash (≈TWD 175 M) versus relatively modest debt (≈TWD 36.6 M), yet the debt‑to‑equity ratio is high at over 7, and cash‑flow generation is negative. With a price‑to‑book of 2.25 and a price‑to‑sales of 3.27, the valuation is not cheap relative to its earnings weakness, and the company does not pay a dividend.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Bullish MACD crossover
  • Price near immediate support at 13
  • Negative earnings and margins

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Revenue growth of ~12% YoY
  • Strong cash position offset by high debt‑to‑equity
  • Continued volatility and sector cyclicality

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • Sustained negative profitability
  • Elevated debt load relative to equity
  • Uncertain turnaround in a competitive semiconductor testing market

Key Metrics & Analysis

Financial Health

Revenue Growth11.80%
Profit Margin-9.15%
ROE-6.01%
ROA-3.73%
Debt/Equity7.28
P/B Ratio2.3
Op. Cash FlowNT$-3725000
Free Cash FlowNT$-12747125
Industry P/E33.7

Technical Analysis

TrendNeutral
RSI45.7
SupportNT$13.00
ResistanceNT$15.10
MA 20NT$14.19
MA 50NT$14.59
MA 200NT$14.19
MACDBullish
VolumeIncreasing
Fear & Greed Index72.88

Valuation

GradeOvervalued
TypeBlend

Risk Assessment

Beta0.70
Volatility32.94%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.